Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease
Sign Up to like & getrecommendations! Published in 2018 at "Bone Marrow Transplantation"
DOI: 10.1038/s41409-017-0081-5
Abstract: Inhibition of the Janus-associated kinases (JAK) with ruxolitinib (RUX) reduces graft-versus-host disease (GVHD) in preclinical and clinical models. In total 19 allograft recipients with moderate/severe steroid-dependent chronic GVHD received RUX as ≥2nd line salvage. RUX… read more here.
Keywords: steroid sparing; sparing agent; versus host; agent chronic ... See more keywords
Efficacy of leflunomide as a steroid-sparing agent in treatment of Indian giant cell arteritis patients: A 2-year follow-up study.
Sign Up to like & getrecommendations! Published in 2022 at "International journal of rheumatic diseases"
DOI: 10.1111/1756-185x.14319
Abstract: OBJECTIVES To evaluate the effectiveness of leflunomide as a steroid-sparing agent among Indian patients with giant cell arteritis (GCA) and to assess the changes of "halo sign" within affected arteries, detected ultrasonographically, after remission. METHODS… read more here.
Keywords: sparing agent; giant cell; steroid sparing; study ... See more keywords